14.22 USD
+0.06 (+0.42%)
HCM gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. HCM has only an average score on both its financial health and profitability. HCM is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year HCM was profitable.
HCM had a negative operating cash flow in the past year.
In multiple years HCM reported negative net income over the last 5 years.
In multiple years HCM reported negative operating cash flow during the last 5 years.
1.2 Ratios
HCM's Return On Assets of 26.29% is amongst the best of the industry. HCM outperforms 98.96% of its industry peers.
Looking at the Return On Equity, with a value of 37.99%, HCM belongs to the top of the industry, outperforming 97.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.29% | ||
| ROE | 37.99% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 77.53%, HCM belongs to the top of the industry, outperforming 99.48% of the companies in the same industry.
HCM's Gross Margin of 44.15% is fine compared to the rest of the industry. HCM outperforms 61.46% of its industry peers.
HCM's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 77.53% | ||
| GM | 44.15% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.54%
GM growth 5Y15.38%
2. Health
2.1 Basic Checks
HCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
HCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
HCM has an Altman-Z score of 3.52. This indicates that HCM is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of HCM (3.52) is better than 69.27% of its industry peers.
HCM has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.08, HCM perfoms like the industry average, outperforming 52.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.52 |
ROIC/WACCN/A
WACC9.11%
2.3 Liquidity
HCM has a Current Ratio of 4.65. This indicates that HCM is financially healthy and has no problem in meeting its short term obligations.
HCM has a Current ratio of 4.65. This is in the better half of the industry: HCM outperforms 63.02% of its industry peers.
A Quick Ratio of 4.51 indicates that HCM has no problem at all paying its short term obligations.
HCM's Quick ratio of 4.51 is fine compared to the rest of the industry. HCM outperforms 64.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.65 | ||
| Quick Ratio | 4.51 |
3. Growth
3.1 Past
HCM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1172.34%, which is quite impressive.
Looking at the last year, HCM shows a decrease in Revenue. The Revenue has decreased by -1.41% in the last year.
Measured over the past years, HCM shows a very strong growth in Revenue. The Revenue has been growing by 25.20% on average per year.
EPS 1Y (TTM)1172.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1661.49%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y20.96%
Revenue growth 5Y25.2%
Sales Q2Q%-9.16%
3.2 Future
HCM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.63% yearly.
HCM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.25% yearly.
EPS Next Y900.95%
EPS Next 2Y81.49%
EPS Next 3Y57.45%
EPS Next 5Y52.63%
Revenue Next Year-11.78%
Revenue Next 2Y0.94%
Revenue Next 3Y6.11%
Revenue Next 5Y20.25%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 5.23, which indicates a rather cheap valuation of HCM.
Based on the Price/Earnings ratio, HCM is valued cheaply inside the industry as 95.83% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.46, HCM is valued rather cheaply.
A Price/Forward Earnings ratio of 33.94 indicates a quite expensive valuation of HCM.
HCM's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. HCM is cheaper than 71.88% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of HCM to the average of the S&P500 Index (36.10), we can say HCM is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.23 | ||
| Fwd PE | 33.94 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
HCM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HCM's earnings are expected to grow with 57.45% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y81.49%
EPS Next 3Y57.45%
5. Dividend
5.1 Amount
HCM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:HCM (12/5/2025, 8:25:47 PM)
14.22
+0.06 (+0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners21.97%
Inst Owner Change-5.06%
Ins Owners0.58%
Ins Owner ChangeN/A
Market Cap2.44B
Revenue(TTM)602.20M
Net Income(TTM)466.88M
Analysts83.7
Price Target16.58 (16.6%)
Short Float %0.37%
Short Ratio9.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.76%
PT rev (3m)-4.81%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.48%
EPS NY rev (3m)4.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.23 | ||
| Fwd PE | 33.94 | ||
| P/S | 4.06 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.99 | ||
| P/tB | 1.99 | ||
| EV/EBITDA | N/A |
EPS(TTM)2.72
EY19.13%
EPS(NY)0.42
Fwd EY2.95%
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS3.5
BVpS7.15
TBVpS7.15
PEG (NY)0.01
PEG (5Y)N/A
Graham Number20.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.29% | ||
| ROE | 37.99% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 77.53% | ||
| GM | 44.15% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.54%
GM growth 5Y15.38%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 221.94% | ||
| Cap/Sales | 4.5% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.65 | ||
| Quick Ratio | 4.51 | ||
| Altman-Z | 3.52 |
F-Score5
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)321.95%
Cap/Depr(5y)304.39%
Cap/Sales(3y)5.11%
Cap/Sales(5y)5.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1172.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1661.49%
EPS Next Y900.95%
EPS Next 2Y81.49%
EPS Next 3Y57.45%
EPS Next 5Y52.63%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y20.96%
Revenue growth 5Y25.2%
Sales Q2Q%-9.16%
Revenue Next Year-11.78%
Revenue Next 2Y0.94%
Revenue Next 3Y6.11%
Revenue Next 5Y20.25%
EBIT growth 1Y83.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.89%
EBIT Next 3Y51.23%
EBIT Next 5Y43.18%
FCF growth 1Y-2591.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-168.32%
OCF growth 3YN/A
OCF growth 5YN/A
HUTCHMED CHINA-ADR / HCM FAQ
Can you provide the ChartMill fundamental rating for HUTCHMED CHINA-ADR?
ChartMill assigns a fundamental rating of 5 / 10 to HCM.
What is the valuation status of HUTCHMED CHINA-ADR (HCM) stock?
ChartMill assigns a valuation rating of 5 / 10 to HUTCHMED CHINA-ADR (HCM). This can be considered as Fairly Valued.
Can you provide the profitability details for HUTCHMED CHINA-ADR?
HUTCHMED CHINA-ADR (HCM) has a profitability rating of 4 / 10.
Can you provide the financial health for HCM stock?
The financial health rating of HUTCHMED CHINA-ADR (HCM) is 5 / 10.